ACTB-1003

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H26F5N7O3
Molecular Weight	591.5325
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COCC1=C(CN2CCOCC2)N3N=CN=C(N)C3=C1C4=CC=C(NC(=O)NC5=CC(=CC=C5F)C(F)(F)F)C(F)=C4

InChI

InChIKey=GZPJCJKUZPUFAL-UHFFFAOYSA-N

InChI=1S/C27H26F5N7O3/c1-41-13-17-22(12-38-6-8-42-9-7-38)39-24(25(33)34-14-35-39)23(17)15-2-5-20(19(29)10-15)36-26(40)37-21-11-16(27(30,31)32)3-4-18(21)28/h2-5,10-11,14H,6-9,12-13H2,1H3,(H2,33,34,35)(H2,36,37,40)

HIDE SMILES / InChI

Molecular Formula	C27H26F5N7O3
Molecular Weight	591.5325
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.sciencedirect.com/science/article/pii/S1359634910718462 | http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665 | http://www.eddingpharm.com/content.aspx?id=52 | http://adisinsight.springer.com/drugs/800030669

ACTB-1003 is an oral kinase inhibitor targeting cancer mutations (FGFR inhibition), angiogenesis (inhibition of VEGFR2 and Tie-2) and induces apoptosis (targeting RSK and p70S6K, downstream of PI3 kinase). The multi-activity of ACTB- 1003 translates to in vivo efficacy with dose-dependent tumor growth inhibition in a variety of histological cancers including lung, breast and colorectal. Eddingpharm acquired worldwide rights to small molecule drug assets including ACTB1003 from ACT Biotech. Eddingpharm plans a phase I trial for Cancer in USA.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Fibroblast growth factor receptor 1 46 Target ID: CHEMBL3650 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665	Inhibitor 8504	6.0 nM [IC50]
Vascular endothelial growth factor receptor 2 112 Target ID: CHEMBL279 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665	Inhibitor 8504	2.0 nM [IC50]
Tyrosine-protein kinase TIE-2 6 Target ID: CHEMBL4128 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665	Inhibitor 8504	4.0 nM [IC50]
CHEMBL3832633: Ribosomal protein S6 kinase 1 Target ID: CHEMBL3832633: Ribosomal protein S6 kinase Sources: http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665	Inhibitor 8504	5.0 nM [IC50]
Ribosomal protein S6 kinase (P70S6K) 3 Target ID: CHEMBL2111330 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665	Inhibitor 8504	32.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: http://www.sciencedirect.com/science/article/pii/S1359634910718462 http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665	Primary		Phase I 438	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00GUHC	https://www.1pchem.com/search?query=1P00GUHC
ApexBio Technology	B4904	https://www.apexbt.com/catalogsearch/result/?q=B4904
AstaTech	F17368	http://astatechinc.com/CPSResult.php?CRNO=F17368
BLD Pharm	BD631041	http://www.bldpharm.com/search/Search.html?keyword=BD631041
Chem Scene	CS-3723	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3723
ChemShuttle	169447	https://www.chemshuttle.com/catalogsearch/result/?q=169447
Debye Scientific	DA-40320	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-40320
eMolecules	50550790	https://orderbb.emolecules.com/search/#?query=50550790
Excenen	EX-A536	http://www.excenen.com/searchresultlist.php?id=EX-A536
mcule	MCULE-3175501889	https://mcule.com/MCULE-3175501889/
MedChem Express	HY-16025	https://www.medchemexpress.com/search.html?q=HY-16025&ft=&fa=&fp=
Molnova	M19271	https://www.molnova.com/en/serch-list.html?keywords=M19271
MolPort	MolPort-046-201-087	https://www.molport.com/shop/molecule-link/MolPort-046-201-087
MuseChem	I005583	https://www.musechem.com/product/I005583.html
ShangHai Biochempartner	BCP13578	http://www.biochempartner.com/search_BCP13578
TargetMol	T4318	https://www.targetmol.com/search?keyword=T4318
Toronto Research Chemicals	A128640	https://www.trc-canada.com/product-detail/?CatNum=A128640

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:52:22 GMT 2025` Edited by `admin` on `Mon Mar 31 22:52:22 GMT 2025`
Record UNII	44750KD9OE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACTB-1003

Common Name

English

UREA, N-(4-(4-AMINO-6-(METHOXYMETHYL)-7-(4-MORPHOLINYLMETHYL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-5-YL)-2-FLUOROPHENYL)-N'-(2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL)-

Preferred Name

English

Code System Code Type Description

NCI_THESAURUS

C164211

Created by admin on Mon Mar 31 22:52:22 GMT 2025 , Edited by admin on Mon Mar 31 22:52:22 GMT 2025

PRIMARY

CAS

939805-30-8

Created by admin on Mon Mar 31 22:52:22 GMT 2025 , Edited by admin on Mon Mar 31 22:52:22 GMT 2025

PRIMARY

PUBCHEM

23653175

Created by admin on Mon Mar 31 22:52:22 GMT 2025 , Edited by admin on Mon Mar 31 22:52:22 GMT 2025

PRIMARY

FDA UNII

44750KD9OE

Created by admin on Mon Mar 31 22:52:22 GMT 2025 , Edited by admin on Mon Mar 31 22:52:22 GMT 2025

PRIMARY

Related Record Type Details


					44750KD9OE

ACTB-1003

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: http://www.sciencedirect.com/science/article/pii/S1359634910718462 | http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665 | http://www.eddingpharm.com/content.aspx?id=52 | http://adisinsight.springer.com/drugs/800030669

Originator

Approval Year

Targets

Conditions

Approved Use

Sourcing

Patents

Sample Use Guides

Description
Sources: http://www.sciencedirect.com/science/article/pii/S1359634910718462 | http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13665 | http://www.eddingpharm.com/content.aspx?id=52 | http://adisinsight.springer.com/drugs/800030669